Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Qwerty54321on Dec 10, 2024 1:54am
103 Views
Post# 36354074

RE:Further clarity needed & size of mkt.

RE:Further clarity needed & size of mkt.

I thought the efficacy data was vague, not in typical 'RECIST language' hard to gauge other than there is a little something there.

No mention of going back to FDA for chat so where's the path forward?

Also no suggestion of committing more cash.

So what then? Parked until partner???


Wino115 wrote: Some of those articles or reports make it seem like they will enhance the dose for whomever is still in the protocol.  Bit confusing to me and they need to clarify next steps.  I also had thought they always had the ability to add another 4-5 people after the high-dose was done if they wanted. Wasn't it always stated for part 3 as 6 at low-dose, 6 at high dose, potential to go 10 at high dose or more?

Lastly - 13,000 women die a year of ovarian and I would assume that's essentially their market as a heavily pre-treated therapy.  It's still the fifth biggest cancer for women and growing in younger generations due to obesity (evidently). 

 

<< Previous
Bullboard Posts
Next >>